ECSP099614A - Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno - Google Patents
Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogenoInfo
- Publication number
- ECSP099614A ECSP099614A EC2009009614A ECSP099614A ECSP099614A EC SP099614 A ECSP099614 A EC SP099614A EC 2009009614 A EC2009009614 A EC 2009009614A EC SP099614 A ECSP099614 A EC SP099614A EC SP099614 A ECSP099614 A EC SP099614A
- Authority
- EC
- Ecuador
- Prior art keywords
- arthritis
- disease
- cartilage
- chronic
- injury
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010003246 arthritis Diseases 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000002574 reactive arthritis Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010003267 Arthritis reactive Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000025940 Back injury Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 abstract 1
- 208000005243 Chondrosarcoma Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000002849 chondrocalcinosis Diseases 0.000 abstract 1
- 208000017568 chondrodysplasia Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000003252 repetitive effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89345307P | 2007-03-07 | 2007-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099614A true ECSP099614A (es) | 2009-10-30 |
Family
ID=39535719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009614A ECSP099614A (es) | 2007-03-07 | 2009-09-07 | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7846953B2 (OSRAM) |
| EP (1) | EP2129668A1 (OSRAM) |
| JP (1) | JP2010520306A (OSRAM) |
| KR (1) | KR20090127410A (OSRAM) |
| CN (1) | CN101679322A (OSRAM) |
| AR (1) | AR065655A1 (OSRAM) |
| AU (1) | AU2008222745A1 (OSRAM) |
| BR (1) | BRPI0808445A2 (OSRAM) |
| CA (1) | CA2679944A1 (OSRAM) |
| CL (1) | CL2008000670A1 (OSRAM) |
| CO (1) | CO6231008A2 (OSRAM) |
| EA (1) | EA200970837A1 (OSRAM) |
| EC (1) | ECSP099614A (OSRAM) |
| IL (1) | IL200757A0 (OSRAM) |
| MX (1) | MX2009009517A (OSRAM) |
| NI (1) | NI200900163A (OSRAM) |
| NZ (1) | NZ579372A (OSRAM) |
| SV (1) | SV2009003367A (OSRAM) |
| TW (1) | TW200902508A (OSRAM) |
| UA (1) | UA98485C2 (OSRAM) |
| WO (1) | WO2008109727A1 (OSRAM) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| MX2009009517A (es) * | 2007-03-07 | 2009-09-16 | Janssen Pharmaceutica Nv | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno. |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| WO2009033703A1 (en) | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| ES2365966T3 (es) | 2007-09-14 | 2011-10-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas. |
| BRPI0816767B8 (pt) | 2007-09-14 | 2021-05-25 | Addex Pharmaceuticals Sa | composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos |
| ES2637794T3 (es) | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2 |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| BRPI0920354A2 (pt) | 2008-10-16 | 2017-06-27 | Addex Pharmaceuticals Sa | derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos |
| CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
| EP2383263B1 (en) * | 2008-12-30 | 2014-04-16 | Industry-academic Cooperation Foundation, Chosun University | Novel thiazolidinedione derivative and use thereof |
| US8729239B2 (en) | 2009-04-09 | 2014-05-20 | Nuclea Biotechnologies, Inc. | Antibodies against fatty acid synthase |
| SG176021A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
| MX2011012267A (es) * | 2009-05-19 | 2012-04-11 | Vivia Biotech Sl | Metodos para proveer pruebas de medicina personalizadas ex vivo en cuanto a neoplasmas hematologicos. |
| US8927297B2 (en) * | 2009-08-11 | 2015-01-06 | Janssen Pharmaceutica N.V. | Methods to measure dissociation rates for ligands that form reversible covalent bonds |
| WO2011019556A1 (en) | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | CO-CRYSTALLIZATION OF ERR-A α WITH A LIGAND THAT FORMS A REVERSIBLE CONVALENT BOND |
| US8685891B2 (en) | 2009-08-27 | 2014-04-01 | Nuclea Biotechnologies, Inc. | Method and assay for determining FAS expression |
| CN102638980A (zh) * | 2009-10-09 | 2012-08-15 | 俄亥俄州州立大学研究基金会 | 噻唑烷二酮能量限制拟似剂 |
| CA2805245A1 (en) * | 2010-07-28 | 2012-02-02 | Orchid Research Laboratories Ltd. | Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases |
| PT2649069E (pt) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2 |
| CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| ES2390303B1 (es) * | 2011-04-11 | 2013-09-16 | Servicio Andaluz De Salud | Compuestos y composiciones para el tratamiento de mieloma múltiple. |
| WO2012140300A1 (es) * | 2011-04-11 | 2012-10-18 | Servicio Andaluz De Salud | Compuestos y composiciones para el tratamiento de mieloma múltiple |
| USD688465S1 (en) | 2011-06-14 | 2013-08-27 | Telebrands Corp. | Hair detangler |
| TW201311679A (zh) | 2011-08-04 | 2013-03-16 | Takeda Pharmaceutical | 含氮雜環化合物 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CA2868311C (en) | 2012-03-26 | 2021-06-22 | Nippon Chemiphar Co., Ltd. | Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| EP3050573B1 (en) | 2013-09-25 | 2019-12-11 | Nippon Chemiphar Co., Ltd. | Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma |
| HUE045610T2 (hu) | 2014-01-21 | 2020-01-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk |
| PH12021552653A1 (en) | 2014-01-21 | 2023-07-17 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| EP4349414B1 (en) | 2014-12-23 | 2025-10-15 | Dyve Biosciences, Inc. | Formulations for transdermal administration |
| CA3002709A1 (en) | 2015-11-02 | 2017-05-11 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| US20190083527A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Method of administration and treatment |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| IL289510B2 (en) * | 2019-07-04 | 2025-08-01 | Lead Pharma Holding Bv | Estrogen-related receptor alpha (erralpha) modulators |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
| KR20220084355A (ko) * | 2019-10-18 | 2022-06-21 | 리드 파마 홀딩 비.브이. | 에스트로겐-관련 수용체 알파 조절제 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037842A (en) | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| JPH09176162A (ja) * | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
| JP2001072592A (ja) * | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| US20060014812A1 (en) * | 2004-07-14 | 2006-01-19 | Player Mark R | Use of estrogen related receptor-modulating aryl ethers |
| US7977489B2 (en) | 2004-10-22 | 2011-07-12 | Exelixis, Inc. | Benzylthiazolone inhibitors of estrogen-related receptors (ERR) |
| MX2009009517A (es) * | 2007-03-07 | 2009-09-16 | Janssen Pharmaceutica Nv | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno. |
| US8119669B2 (en) * | 2007-03-07 | 2012-02-21 | Janssen Pharmaceutica N.V. | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators |
-
2008
- 2008-03-06 MX MX2009009517A patent/MX2009009517A/es active IP Right Grant
- 2008-03-06 JP JP2009552881A patent/JP2010520306A/ja active Pending
- 2008-03-06 US US12/043,269 patent/US7846953B2/en not_active Expired - Fee Related
- 2008-03-06 UA UAA200910123A patent/UA98485C2/ru unknown
- 2008-03-06 CN CN200880015196A patent/CN101679322A/zh active Pending
- 2008-03-06 AU AU2008222745A patent/AU2008222745A1/en not_active Abandoned
- 2008-03-06 CL CL2008000670A patent/CL2008000670A1/es unknown
- 2008-03-06 NZ NZ579372A patent/NZ579372A/en not_active IP Right Cessation
- 2008-03-06 WO PCT/US2008/056004 patent/WO2008109727A1/en not_active Ceased
- 2008-03-06 EP EP08731504A patent/EP2129668A1/en not_active Ceased
- 2008-03-06 CA CA002679944A patent/CA2679944A1/en not_active Abandoned
- 2008-03-06 TW TW097107941A patent/TW200902508A/zh unknown
- 2008-03-06 KR KR1020097020449A patent/KR20090127410A/ko not_active Withdrawn
- 2008-03-06 BR BRPI0808445-9A patent/BRPI0808445A2/pt not_active IP Right Cessation
- 2008-03-06 EA EA200970837A patent/EA200970837A1/ru unknown
- 2008-03-07 AR ARP080100962A patent/AR065655A1/es not_active Application Discontinuation
-
2009
- 2009-09-04 NI NI200900163A patent/NI200900163A/es unknown
- 2009-09-06 IL IL200757A patent/IL200757A0/en unknown
- 2009-09-07 EC EC2009009614A patent/ECSP099614A/es unknown
- 2009-09-07 SV SV2009003367A patent/SV2009003367A/es unknown
- 2009-09-11 CO CO09097934A patent/CO6231008A2/es not_active Application Discontinuation
-
2010
- 2010-10-07 US US12/899,812 patent/US8344009B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2679944A1 (en) | 2008-09-12 |
| BRPI0808445A2 (pt) | 2014-08-05 |
| US7846953B2 (en) | 2010-12-07 |
| CN101679322A (zh) | 2010-03-24 |
| TW200902508A (en) | 2009-01-16 |
| IL200757A0 (en) | 2010-05-17 |
| CL2008000670A1 (es) | 2008-11-03 |
| MX2009009517A (es) | 2009-09-16 |
| US8344009B2 (en) | 2013-01-01 |
| WO2008109727A8 (en) | 2009-12-17 |
| SV2009003367A (es) | 2010-08-10 |
| AR065655A1 (es) | 2009-06-24 |
| EP2129668A1 (en) | 2009-12-09 |
| UA98485C2 (ru) | 2012-05-25 |
| US20110237625A1 (en) | 2011-09-29 |
| EA200970837A1 (ru) | 2010-04-30 |
| US20090111855A1 (en) | 2009-04-30 |
| AU2008222745A1 (en) | 2008-09-12 |
| CO6231008A2 (es) | 2010-12-20 |
| NZ579372A (en) | 2012-02-24 |
| KR20090127410A (ko) | 2009-12-11 |
| JP2010520306A (ja) | 2010-06-10 |
| NI200900163A (es) | 2010-07-22 |
| WO2008109727A1 (en) | 2008-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099614A (es) | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno | |
| UA98484C2 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ КАК МОДУЛЯТОРЫ α-РЕЦЕПТОРА ЭСТРОГЕНА | |
| MX2009009519A (es) | Fenoxitiazolidinodionas n-alquiladas sustituidas como moduladores de receptor- alfa relacionados con estrogeno. | |
| TW201144303A (en) | Aminothiazolones as estrogen related receptor-α modulators | |
| MX2012009528A (es) | Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. | |
| AU2008262871B2 (en) | Amine compound and pharmaceutical use thereof | |
| JP2012506473A5 (OSRAM) | ||
| JP2010520308A5 (OSRAM) | ||
| TW201821468A (zh) | 環氧樹脂、環氧樹脂組成物、環氧樹脂硬化物及複合材料 | |
| CY1123495T1 (el) | Σουλφοναμιδια ως αγωνιστες των gpr40 και gpr120 | |
| JP2011516700A5 (OSRAM) | ||
| RU2019133488A (ru) | Препрег и армированный углеродным волокном композитный материал | |
| US20170253555A1 (en) | Polymerizable monomer, method of producing polymerizable monomer, curable composition and resin member | |
| JP5204670B2 (ja) | ポリスルフィドを調製する方法、ポリスルフィド、およびその使用方法 | |
| UA97975C2 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛОВАННЫЕ ТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α | |
| JP2012233153A5 (OSRAM) | ||
| JP2011207805A (ja) | チオエーテル基を有するベンゾオキサジン誘導体およびその製造法 | |
| CO6140057A2 (es) | Nuevos compuestos cristalinos | |
| CY1111495T1 (el) | Νεα παραγωγα του 3-φαινυλο-προπανοϊκου οξεος, ενεργοποιητες των υποδοχεων τυπου ppar, μεθοδος παρασκευης τους και χρηση αυτων σε κοσμητικες ή φαρμακευτικες συνθεσεις | |
| KR102264925B1 (ko) | 고굴절률 경화성 화합물, 이를 포함하는 광학부재용 점착제 조성물 및 이를 포함하는 광학시트용 조성물 | |
| JP5753717B2 (ja) | 芳香族スルフィド化合物の製造方法 | |
| JP2012031413A5 (OSRAM) | ||
| PL397314A1 (pl) | Sposób otrzymywania zywicy dimetakrylanowej zwlaszcza do cementu kostnego | |
| JP2016023176A (ja) | 化合物及びその製造方法 | |
| ES2383085T3 (es) | Composiciones fotopolimerizables caracterizadas por un nuevo acelerador amina para mejorar la estabilidad del color y reducir de este modo el estrés de polimerización |